Immuno-Oncology Xchange
East Coast 2021
May 25 & 27

Welcome to hubXchange’s virtual East Coast Immuno-Oncology Xchange 2021, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies. 
Discussion topics will cover Immune Biomarkers & Translational Research, Preclinical Research, Clinical Development, Cell Therapies and Next-Generation Therapies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Immune Biomarkers & Translational Research

Time
Titles and Bullets
Facilitator
8:30am – 9:00am

DAY 1 (May 25, 2021) 
8:30am – 9:00am

Opening Address & Keynote: 
9:10 – 10:10am
Sponsor-led Roundtable Topic TBC
10:10 – 11:00am
BREAK
11:00 – 11:30am
1-2-1 Meetings

11:30am – 12:00pm
1-2-1 Meetings

12:00 – 1:00pm
BREAK
1:00 – 1:30pm
1-2-1 Meetings
1:40 – 2:40pm
Predicting patient responses to Immune Checkpoint Inhibitors Topic TBC

Vice President, Head, In Vivo Pharm & Translational Sciences
Elstar Therapeutics

 

Portrait picture of Sangeetha Palakurthi
DAY 2 (May 27, 2021)
8:30 – 9:00am
Keynote Presentation
9:10 – 10:10am
Integrating biomarker data and clinical response data from IO based clinical trials
  • How do we optimize early stage clinical study design for exploratory biomarker development?
  • How do we take advantage of peripheral immune components (autoantibodies, exosomes, T cell markers, etc.) to understand the tumor immune micro-environment?
  • Current diagnostic criteria in cancer immunotherapy doesn’t accurately identify subjects likely to respond.  How do we use what’s available develop rational combination therapies with other immunotherapies or chemotherapies? 

Director, Translational Biology
Macrogenics

Patrick Kaminker is an industry scientist that received his degree in Pharmacology from the University of Kentucky. After focusing his postdoctoral studies on the intersection of telomeres with aging and cancer in Dr. Judy Campisi’s lab at the Lawrence Berkeley National Labs he joined the Buck Institute for Age Research. Dr. Kaminker then spent several years at Celera and Human Genome Sciences in the pursuit of novel targeted cancer therapies. He took an interest in translational research while at Human Genome Sciences while looking for biomarkers associated with TRAIL agonists and how a certain population had shown durable anti-tumor activity associated with certain immune signatures. Since that time, he has been focused on the translational aspects of multiple classes of therapeutics including: epigenetic modifiers, antibody-drug conjugates, and recently cancer immunotherapies and currently runs the translational group at Macrogenics.

10:20 – 11:00am
BREAK
11:00 – 11:30am
1-2-1 Meetings
11:30am – 12:00pm
1-2-1 Meetings
12:00 – 1:00pm
Break

1:00 – 1:30pm

Poster Session

Abstract TBC

1:40 – 2:40pm

Decoding the immune system to uncover novel biomarkers to support the development of more efficacious therapies

Head, Immuno-Oncology Biology & Translation
Takeda Oncology

Portrait picture of Katherine Seidl
2:40 – 2:45pm
Closing Address

Partners

Immuno-Oncology Xchange | East Coast 2021
Register